|
|
Article: United States: Trinity Biotech plc Signs Agreement With Akers Biosciences for Distribution of ABI Heparin Allergy Test.
- Article from:
- TendersInfo
- Article date:
- June 27, 2008
CopyrightCOPYRIGHT 2008 Al Bawaba (Middle East) Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: sandesh03
Trinity Biotech plc is pleased to announce that it has been appointed by Akers Biosciences, Inc (LSE: AKR) ('ABI'), a leading designer and manufacturer of rapid diagnostic screening and testing products, as a distributor of its unique PIFA Heparin/Platelet Factor-4 Rapid Assay (HPF4) in the USA and German markets.
Heparin is the most widely used intravenous anticoagulant, and is commonly used for the prophylaxis and treatment of thromboembolic disease. It also has numerous other applications such as the treatment of certain types of lung and heart disorders and after a variety of surgeries including open heart, bypass, orthopedic ...